Fig. 7: DYNE−101 low repeat monthly dosing reduces DMPK expression in muscle of TfR1hu/mu;DMSXLWT/Tg mice. | Communications Medicine

Fig. 7: DYNE−101 low repeat monthly dosing reduces DMPK expression in muscle of TfR1hu/mu;DMSXLWT/Tg mice.

From: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

Fig. 7

Mutant human DMPK expression measured by RT-qPCR in muscle of TfR1hu/mu;DMSXLWT/Tg male and female mice a 1 month after a single IV injection with DYNE−101 (blue bars) or b 1 month following the last of 4 monthly doses at the indicated ASO-equivalent doses (blue bars), relative to expression in the same muscles of mice injected with vehicle (black bars). Data are means + SD; data were analyzed by one-way ANOVA followed by uncorrected Fisher’s LSD test, statistically significant differences from vehicle or between DYNE-101 dose levels are indicated with exact P values. Each circle represents an individual mouse.

Back to article page